CISEN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.84 CNY | -0.25% |
|
+6.67% | +8.20% |
| 23/04 | Cisen Pharmaceutical Names Chief Financial Officer | MT |
| 22/04 | Cisen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 4.07B 562M 46.9B | Sales 2023 | 4.46B 617M 51.47B | Capitalization | 6.6B 913M 76.13B |
|---|---|---|---|---|---|
| Net income 2022 | 350M 48.4M 4.04B | Net income 2023 | 521M 72.04M 6.01B | EV / Sales 2022 | 0.75 x |
| Net cash position 2022 | 2.63B 363M 30.28B | Net cash position 2023 | 2.6B 360M 30.04B | EV / Sales 2023 | 0.9 x |
| P/E ratio 2022 |
16.4
x | P/E ratio 2023 |
12.7
x | Employees | 3,402 |
| Yield 2022 |
2.66% | Yield 2023 |
2.98% | Free-Float | 37.78% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.25% | ||
| 1 week | +6.67% | ||
| Current month | +10.31% | ||
| 1 month | +11.24% | ||
| 3 months | +3.73% | ||
| 6 months | +13.30% | ||
| Current year | +8.20% |
1 week
15.32
16.35
1 month
14.4116.35
Current year
11.3416.41
1 year
11.3416.93
3 years
10.3016.93
5 years
10.3020.65
10 years
10.3032.73
| Managers | Title | Age | Since |
|---|---|---|---|
Zhen Xin Du
CEO | Chief Executive Officer | 57 | 06/98/06 |
En Long Zhao
CHM | Chairman | 45 | 01/04/01 |
Xin Bang Xu
DFI | Director of Finance/CFO | 46 | 01/00/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Zhang
BRD | Director/Board Member | 59 | 28/17/28 |
Zhen Xin Du
CEO | Chief Executive Officer | 57 | 06/98/06 |
Xin Sheng Sun
BRD | Director/Board Member | 71 | 28/17/28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 15.84 | -0.25% | 4 540 933 |
| 26/24/26 | 15.88 | -1.24% | 5,265,387 |
| 25/24/25 | 16.08 | +0.82% | 6,333,850 |
| 24/24/24 | 15.95 | +2.97% | 6,741,115 |
| 23/24/23 | 15.49 | +1.64% | 10,423,500 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
Cisen Pharmaceutical Co., Ltd is a China-based company principally involved in the research, development, manufacturing and sales of medical products. The Company operates through two main segments. The Main Business segment is primarily involved in the manufacturing and sales of medicine, among which include infusion, freeze-dried powder, small volume injection, tablet, capsules, ointment, drops and active pharmaceutical ingredients, among others. The Other Business segment is mainly involved in the sales of raw materials and houses tenancy.
Sector
Pharmaceuticals
Calendar
21/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +8.20% | 992M | |
| +20.81% | 43.34B | |
| +20.44% | 21.96B | |
| +13.30% | 14.09B | |
| +12.97% | 13.64B | |
| +39.74% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 603367 Stock
